Rhombencephalitis A Series of 97 Patients
Medicine 90:256-261, Moragas, M.,et al, 2011
Internuclear Ophthalmoplegia
Arch Neurol 62:714-717, Keane,J.R., 2005
MR Features of Diseases Involving Bilateral Middle Cerebellar Peduncles
AJNR 24:1946-1954, Okamoto,K.,et al, 2003
Isolated Cranial Nerve Palsies Due to Brainstem Lesions
Muscle & Nerve 22:1168-1176, Thomke,F., 1999
Twelfth-Nerve Palsy:Analysis of 100 Cases
Arch Neurol 53:561-566, Keane,J.R., 1996
Clinical, Neurodiagnostic, and MR Findings in Children with Spinal & Brain Stem Multiple Sclerosis
AJNR 16:87-95, Glasier,C.M.,et al, 1995
Tumoral Multiple Sclerosis of the Cerebellum in a Child
AJNR 16:1164-1166, Rusin,J.A.,et al, 1995
Intractable Hiccups:The Role of Cerebral MR in Cases Without Systemic Cause
AJNR 16:2093-2100, Marsot-Dupuch,K.,et al, 1995
Convergence-Evoked Nystagmus
Neurol 40:161-162, Oliva,A.&Rosenberg,M.L., 1990
Segmental Myoclonus Clinical and Pharmacologic Study
Arch Neurol 43:1025-1031, Jankovic,J.&Pardo,R., 1986
The One- & -A-Half Syndrome-A Unilateral Disorder of the Pontine Tegmentum:A Study of 20 Cases & Review of the Liter
Neurol 33:971-980, Wall,M.,et al, 1983
Bilateral Sixth Nerve Palsy
Arch Neurol 33:681, Keane,J.R., 1976
Brain Stem Arteriovenous Malformations
Arch Ophthalmol 86:255, Lessel,S.,et al, 1971
Internuclear Ophthalmoplegia, Typical & Atypical
Arch Ophthal 84:583, Cogan,D.G., 1970
Internuclear Ophthalmoplegia as an Early Sign of Brainstem Tumors
Neurol 20:629, Cogan,D.,et al, 1970
Brain Stem Tumors Occuring in Adults
Neurol 13:292, While,H.H., 1963
Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis
Neurol 102:e208006, Ng, HS.,et al, 2024
Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Initial Highly Effective Therapy for MS
Neurol 95:1114-1116, Wallin, M.T., 2020
Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis
JAMA 32:165-174,153, Burt, R.K.,et al, 2019
Drug Reaction with Eosinophilia and Systemic Symptoms after Daclizamub Therapy
Neurol 91:e359-e363, Rauer,S.,et al, 2018
Numb Chin Syndrome
UptoDate.com Sept, Robertson, C.E., 2018
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 376:221-234,280, Hauser, S.L.,et al, 2017
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
NEJM 376:209-220,280, Montalban, X.,et al, 2017
A 34-Year-Old Man with Headache, Diploplia, and Hemiparesis
Neurol 86:e28, Lincoln, M.R.,et al, 2016
Malignancies after Mitoxantrone for Multiple Sclerosis
Neurol 86:2203-2207, Buttmann, M.,et al, 2016
Fulminant Central Nervous System Nocardiosis in a Patient Treated with Alemtuzumab for Relapsing-Remitting Multiple Sclerosis
JAMA Neurol 73:757-759, Penkert, H.,et al, 2016
Reactivation of Herpesvirus under Fingolimod: A Case of Severe Herpes Simplex Encephalitis
Neurol 84:2377-2378, Pfender, N.,et al, 2015
Cardiovascular Dysfunction in Multiple Sclerosis
Neurologist 20:108-114, Kaplan, T.B.,et al, 2015
Mycophenolate Mofetil in Multiple Sclerosis: A Multicentre Retrospective Study on 344 Patients
JNNP 85:279-283,246, Michel, L.,et al, 2014
The Etiology of Ring Lesions on Diffusion-Weighted Imaging
NeuroRadiol J 27:280-287, Finelli, P. & Foxman, E.B., 2014
Tumor Necrosis Factor-Alpha Inhibitors: An Overview of Adverse Effects
UpToDate January, Stone, J.H., 2013
Central Nervous System Lymphoma Initial Diagnosed as Tumefective Multiple Sclerosis after Brian Biopsy
Intern Med 52:483-488, Ohe, Y.,et al, 2013
Solitary Sclerosis
Neurol 78:540-544, Schmalstieg,W.F.,et al, 2012
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
NEJM 366:1870-1880,1938, Bloomgren, G.,et al, 2012
Tumefactive Multiple Sclerosis Lesions under Fingolimod Treatment
Neurol 79:2000-2002,1942, Visser, F.,et al, 2012
Severe Relapses under Fingolimod Treatment Prescribed after Natalizumab
Neurol 79:2004-2006,1942, Centonze, D.,et al, 2012
Multiple Sclerosis Rebound Following Herpes Zoster Infection and Suspension of Fingolimod
Neurol 79:2006-2007,1942, Gross, C.M.,et al, 2012
Varicella-Zoster Virus Encephalitis and Vasculopathy in a Patient Treated with Fingolimod
Neurol 79:2002-2004,1942, Ratchford, J.,et al, 2012
The Differential Diagnosis of Longitudinally Extensive Transverse Myelitis
Mult Scler 18:271-285, Kitley, J.L.,et al, 2012
Primary Central Nervous System Lymphoma in a Patient Treated with Natalizumab
Ann Neurol 69:1060-1062, Phan-Ba, R.,et al, 2011
Cost-effectiveness of disease-modifying therapy for multiple sclerosis
Neurol 77:355-363, Noyes, K.,et al, 2011
Optic Neuritis: Prognosis and Treatment
UpToDate, Jan, Osborne, B.,et al, 2011
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
NEJM 365:1293-1303, OConnor, P.,et al, 2011
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
NEJM 362:416-426, 456, Giovannoni,G.,et al, 2010
Progressive Multifocal Leukoencephalopathy: Can We Reduce Risk in Patients Receiving Biological Immunomodulatory Therapies?
Ann Neurol 68:271-274, Tyler,K., 2010
Brainstem Lesion in Clinically Isolated Syndromes
Neurol 75:1933-1938, Tintore,M.,et al, 2010
Evidence for Acute Neurotoxicity After Chemotherapy
Ann Neurol 68:806-815, Petzold,A.,et al, 2010